Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...

After raising an impressive 1.2 billion euros in 2024, European venture capital firm Sofinnova Partners is topping up its ...

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

Amgen (AMGN) gains traction with a 26% YTD rise, strong earnings, and a robust dividend. Analysts signal growth potential ...

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

In the latest trading session, Amgen (AMGN) closed at $317.17, marking a +1.1% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.64%. Meanwhile, the Dow experienced a rise ...